22 unknown. 22 Phase 4.
| Phase | Trials | Status |
|---|---|---|
| Phase 4 | 22 | Unknown 22 |
Follow Demyelinating Diseases: new trials by email Literature Review of Demyelinating Diseases trials Research Report on Demyelinating Diseases
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| A Clinical Research Study of Inebilizumab in Neuromyelitis Optica Spectrum Disorders Inebilizumab - Neuromyelitis Optica Spectrum Disorders | Phase 4 | Unknown | Hansoh BioMedical R&D Company | 33 | 2024-02-25 | 2024-01-18 |
| Immunogenicity of the Recombinant Zoster Vaccine in Multiple Sclerosis Patients recombinant zoster vaccine - Shingles, Zoster | Phase 4 | Unknown | Prof Patrice Lalive | 100 | 2022-12-01 | 2024-04-10 |
| Investigating the Effects of Hydroxyvitamin D3 on Multiple Sclerosis 25(OH)D3, vitamin D3 - Multiple Sclerosis, Relapsing-Remitting, Adult ALL | Phase 4 | Unknown | Tehran University of Medical Sciences | 54 | 2022-07-01 | 2022-04-22 |
| Effects of Oral Cladribine on Remyelination and Inflammation in Multiple Sclerosis Patients Cladribine 10 mg oral tablet - Multiple Sclerosis, Relapsing-Remitting | Phase 4 | Unknown | Pontificia Universidade Católica do Rio Grande do Sul | 10 | 2021-04-28 | 2024-01-08 |
| A Prospective Biomarker Study in Active SPMS Subjects Treated With Cladribine Tablets Cladribine Tablets - Multiple Sclerosis | Phase 4 | Unknown | Keith Edwards, M.D. | 30 | 2020-09-16 | 2022-01-13 |
| Personalized Extended Interval Dosing of Natalizumab in Relapsing Remitting Multiple Sclerosis Personalized extended interval dosing of natalizumab, Standard interval dosing - Relapsing Remitting Multiple Sclerosis | Phase 4 | Unknown | Amsterdam UMC, location VUmc | 300 | 2020-02-03 | 2023-04-27 |
| A Pilot Study to Characterize the Biological Effect of a Pre-planned 12 Week Dose Interruption of Natalizumab Dosing Interruption of Natalizumab - Multiple Sclerosis, Multiple Sclerosis, Relapsing-Remitting | Phase 4 | Unknown | Berkovich, Regina MD, PhD Inc. | 10 | 2019-07-03 | 2021-07-22 |
| Methylprednisolone During the Switch Between Natalizumab and Fingolimod Methylprednisolone, Placebo, natalizumab (NTZ) - Multiple Sclerosis | Phase 4 | Unknown | University Hospital, Clermont-Ferrand | 56 | 2019-06-12 | 2023-01-09 |
| Evaluating the Use of Prednisone to Decrease Pegylated Interferon Beta-1a Side Effects Plegridy, Prednisone, Tylenol Pill - Multiple Sclerosis | Phase 4 | Unknown | Holy Name Medical Center, Inc. | 50 | 2017-09-25 | 2019-08-15 |
| Mycophenolate Mofetil Treatment With Neuromyelitis Optica Spectrum Disorders in Chinese Patients Mycophenolate mofetil, Prednisone - Neuromyelitis Optica Spectrum Disorders, Mycophenolate Mofetil | Phase 4 | Unknown | Third Affiliated Hospital, Sun Yat-Sen University | 100 | 2016-01-01 | 2016-06-22 |
| IVIg for Demyelination in Diabetes Mellitus 10% intravenous immunoglobulin (IVIg), 0.9% sodium chloride - Peripheral Neuropathy, Diabetes Mellitus | Phase 4 | Unknown | University of Toronto | 25 | 2015-02-01 | 2016-11-11 |
| Investigating Indirect Mechanism of Neuroprotection of Tecfidera® (Dimethyl Fumarate) in RRMS and Progressive Patients dimethyl fumarate - Multiple Sclerosis | Phase 4 | Unknown | Multiple Sclerosis Center of Northeastern New York | 57 | 2015-02-01 | 2018-03-22 |
| Efficacy of Dalfampridine on Upper Extremity Function in Patients With MS Sustained-release oral dalfampridine, Placebo - Multiple Sclerosis | Phase 4 | Unknown | Sheba Medical Center | 30 | 2014-11-01 | 2014-10-08 |
| Study to Assess Immune Function and MRI Disease Activity in RRMS Patients When Switching From Natalizumab to Gilenya Fingolimod, Natalizumab - Relapsing Remitting Multiple Sclerosis | Phase 4 | Unknown | University Hospital Muenster | 15 | 2014-03-01 | 2014-12-25 |
| Antispastic Effect of Transcranial Magnetic Stimulation in Patients With Cerebral and Spinal Spasticity Transcranial magnetic stimulation - Spasticity, Multiple Sclerosis, Stroke, Trauma | Phase 4 | Unknown | Russian Academy of Medical Sciences | 60 | 2013-02-01 | 2014-11-07 |
| Early and Late Prognosis in Patients With Guillain-Barre Syndrome Intravenous Immunoglobulins, Human, Methylprednisolone 500 MG Injection - Guillain-Barre Syndrome | Phase 4 | Unknown | First Affiliated Hospital of Wenzhou Medical University | 450 | 2013-01-02 | 2023-09-18 |
| Impact of Vitamin A on Gene Expression, in Multiple Sclerosis Patient vitamin A - Relapsing Remitting Multiple Sclerosis | Phase 4 | Unknown | Tehran University of Medical Sciences | 30 | 2011-04-01 | 2012-07-18 |
| Impact of Vitamin A on Multiple Sclerosis (MS) vitamin A, Drug: placebo - Relapsing Remitting Multiple Sclerosis | Phase 4 | Unknown | Tehran University of Medical Sciences | 100 | 2010-02-01 | 2011-08-16 |
| Impact of Vitamin A on RAR Gene Expression in Multiple Sclerosis Dietary Supplement: vitamin A, placebo - Relapsing Remitting Multiple Sclerosis | Phase 4 | Unknown | Tehran University of Medical Sciences | 20 | 2010-02-01 | 2012-10-12 |
| Optical Coherence Tomography: Glatiramer in Clinically Isolated Syndrome or Early Relapsing Remitting Multiple Sclerosis (MS) glatiramer acetate - Multiple Sclerosis | Phase 4 | Unknown | Amphia Hospital | 60 | 2009-09-01 | 2010-02-10 |
Showing 20 of 22. Sign in to see all of them.
Multiple Sclerosis (14) · Multiple Sclerosis, Relapsing-Remitting (9) · Neuromyelitis Optica (3) · Diabetes Mellitus (1) · Guillain-Barre Syndrome (1) · Herpes Zoster (1) · Injection Site Reaction (1) · Muscle Spasticity (1) · Peripheral Nervous System Diseases (1) · Polyradiculoneuropathy, Chronic Inflammatory Demyelinating (1) · Precursor Cell Lymphoblastic Leukemia-Lymphoma (1) · Recurrence (1) · Stroke (1) · Wounds and Injuries (1)
Autoimmune Diseases (22) · Autoimmune Diseases of the Nervous System (22) · Immune System Diseases (22) · Nervous System Diseases (22) · Demyelinating Autoimmune Diseases, CNS (20) · Pathological Conditions, Signs and Symptoms (5) · Pathologic Processes (4) · Cranial Nerve Diseases (3) · Disease Attributes (3) · Eye Diseases (3) · Multiple Sclerosis (3) · Myelitis, Transverse (3) · Optic Nerve Diseases (3) · Optic Neuritis (3)
Cholecalciferol (2) · Cladribine (2) · Immunoglobulins, Intravenous (2) · Methylprednisolone (2) · Natalizumab (2) · Prednisone (2) · Vitamin A (2) · Vitamin D (2) · 4-Aminopyridine (1) · Acetaminophen (1) · Calcifediol (1) · Dimethyl Fumarate (1) · Fingolimod Hydrochloride (1) · Glatiramer Acetate (1) · Injections (1)
Tehran University of Medical Sciences (4) · Amphia Hospital (1) · Amsterdam UMC, location VUmc (1) · Berkovich, Regina MD, PhD Inc. (1) · First Affiliated Hospital of Wenzhou Medical University (1) · Hansoh BioMedical R&D Company (1) · Holy Name Medical Center, Inc. (1) · Keith Edwards, M.D. (1) · Multiple Sclerosis Center of Northeastern New York (1) · Pontificia Universidade Católica do Rio Grande do Sul (1) · Prof Patrice Lalive (1) · Russian Academy of Medical Sciences (1) · Sheba Medical Center (1) · Third Affiliated Hospital, Sun Yat-Sen University (1) · University Hospital Muenster (1)
United States (4) · China (3) · Iran (3) · Netherlands (2) · Brazil (1) · Canada (1) · Finland (1) · France (1) · Germany (1) · Israel (1) · Russia (1) · Switzerland (1)
Keith R Edwards, M.D. (2) · Sama Bitarafan, MD, PhD student (2) · Anat Achiron, MD, PhD (1) · Ari Breiner, MD, FRCPC (1) · Arnaud Didierlaurent, Pr (1) · Huiqing Dong, Doctor (1) · Luisa Klotz, PD. Dr. med. (1) · Michael F Holick, PhD,MD (1) · Mohamadali Sahraian, MD (1) · Patrice Lalive, Pr (1) · Regina R Berkovich, MD, PhD (1) · Wei Qiu, Medical PhD (1)
PMID 15304586, PMID 16638802, PMID 17588298, PMID 19752302, PMID 22362918, PMID 25199960, PMID 26161708, PMID 26996107, PMID 30050529, PMID 30258442, PMID 37963723, PMID 39990866, PMID 40988462, PMID 9633761
2015 (1)